186 related articles for article (PubMed ID: 24076172)
21. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
Tao M; Raddatz R; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2011 Oct; 21(20):6126-30. PubMed ID: 21906941
[TBL] [Abstract][Full Text] [Related]
22. Dual histamine H3R/serotonin 5-HT4R ligands with antiamnesic properties: pharmacophore-based virtual screening and polypharmacology.
Lepailleur A; Freret T; Lemaître S; Boulouard M; Dauphin F; Hinschberger A; Dulin F; Lesnard A; Bureau R; Rault S
J Chem Inf Model; 2014 Jun; 54(6):1773-84. PubMed ID: 24857631
[TBL] [Abstract][Full Text] [Related]
23. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
[TBL] [Abstract][Full Text] [Related]
24. Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
Swanson DM; Shah CR; Lord B; Morton K; Dvorak LK; Mazur C; Apodaca R; Xiao W; Boggs JD; Feinstein M; Wilson SJ; Barbier AJ; Bonaventure P; Lovenberg TW; Carruthers NI
Eur J Med Chem; 2009 Nov; 44(11):4413-25. PubMed ID: 19577344
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.
Josef KA; Aimone LD; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jun; 22(12):4198-202. PubMed ID: 22617490
[TBL] [Abstract][Full Text] [Related]
26. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
[TBL] [Abstract][Full Text] [Related]
27. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present).
Łażewska D; Kieć-Kononowicz K
Expert Opin Ther Pat; 2014 Jan; 24(1):89-111. PubMed ID: 24131059
[TBL] [Abstract][Full Text] [Related]
28. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
[TBL] [Abstract][Full Text] [Related]
29. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
30. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
[TBL] [Abstract][Full Text] [Related]
31. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
32. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
[TBL] [Abstract][Full Text] [Related]
33. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.
Raddatz R; Hudkins RL; Mathiasen JR; Gruner JA; Flood DG; Aimone LD; Le S; Schaffhauser H; Duzic E; Gasior M; Bozyczko-Coyne D; Marino MJ; Ator MA; Bacon ER; Mallamo JP; Williams M
J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
Zeng Q; Rosenblum SB; Yang Z; Jiang Y; McCormick KD; Aslanian RG; Duguma L; Kozlowski JA; Shih NY; Hey JA; West RE; Korfmacher WA; Berlin M; Boyce CW
Bioorg Med Chem Lett; 2013 Nov; 23(21):6001-3. PubMed ID: 24050887
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.
Gao Z; Hurst WJ; Guillot E; Nagorny R; Pruniaux MP; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jul; 23(14):4044-7. PubMed ID: 23769643
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
38. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
Sadek B; Schwed JS; Subramanian D; Weizel L; Walter M; Adem A; Stark H
Eur J Med Chem; 2014 Apr; 77():269-79. PubMed ID: 24650714
[TBL] [Abstract][Full Text] [Related]
39. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Brackenborough K; Briggs MA; Brough S; Calver AR; Crook B; Davis RK; Davis RP; Davis S; Dean DK; Harris L; Heslop T; Holland V; Jeffrey P; Panchal TA; Parr CA; Quashie N; Schogger J; Sehmi SS; Stean TO; Steadman JG; Trail B; Wald J; Worby A; Takle AK; Witherington J; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6890-6. PubMed ID: 24269482
[TBL] [Abstract][Full Text] [Related]
40. Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol.
Sadek B; Shehab S; Więcek M; Subramanian D; Shafiullah M; Kieć-Kononowicz K; Adem A
Bioorg Med Chem Lett; 2013 Sep; 23(17):4886-91. PubMed ID: 23891186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
